A5044399684- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pleural and Pulmonary Diseases
- Medical Imaging and Pathology Studies
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Cardiac tumors and thrombi
- Venous Thromboembolism Diagnosis and Management
- Global Cancer Incidence and Screening
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Mycobacterium research and diagnosis
Helios Klinikum Emil von Behring
2016-2025
Clinica de Pneumologie Iaşi
2023
Institut für Lungenforschung
2023
Lungenklinik Hemer
2008-2020
Evangelische Lungenklinik Berlin
2012-2019
University of Duisburg-Essen
2018
Johannes Wesling Klinikum Minden
2014
Heidelberg University
2014
University Hospital Heidelberg
2014
Helios Universitätsklinikum Wuppertal
2014
The long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is described as a potential biomarker for NSCLC (non-small cell cancer). Diagnostic biomarkers need to be detectable in easily accessible body fluids, should characterized by high specificity, sufficient sensitivity, and robustness against influencing factors. aim of this study was evaluate the performance blood based NSCLC.MALAT1 shown cellular fraction peripheral human blood, showing different expression...
Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial for routine diagnostics. Till date these data have been derived mostly from clinical trials, thus collected pre-selected populations. We therefore screened 'allcomers' with a newly diagnosed non-small cell lung carcinoma (NSCLC) frequencies mutations.A cohort study.Lung cancer centre tertiary care hospital.Within 15 months, total 552...
The recent introduction of bronchoscopically recovered cryobiopsy lung tissue has opened up new possibilities in the diagnosis neoplastic and non-neoplastic diseases various aspects. Most notably morphological peripheral biopsies promises to achieve a better yield with high quality specimens. To understand this phenomenon, its diagnostic options perspectives, study morphometrically compares 15 cryobiopsies 18 transbronchial forceps priori without considering clinical hit ratio or integration...
Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC clinical routine, but it has limited value distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate an immunosupportive tumor microenvironment (TME) might help to close this gap.
The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive response thus improve immune-mediated control of residual cancer disease. IMPULSE phase II study evaluated the efficacy safety as maintenance treatment in extensive-stage small-cell lung (ES-SCLC) after objective to first-line chemotherapy, an indication with high unmet medical need stagnant improvement last decades.103 patients ES-SCLC tumor (as per RECIST 1.1) following...
Pembrolizumab is a standard of care as first line palliative therapy in PD-L1 overexpressing (≥50%) non-small cell lung cancer (NSCLC). This study aimed at the identification KRAS and TP53-defined mutational subgroups high population to distinguish long-term responders from those with limited benefit.In this retrospective, observational study, patients 4 certified centers Berlin, Germany, having received pembrolizumab monotherapy treatment for adenocarcinoma (LuAD) 2017 2018, expression...
Large-cell neuroendocrine carcinoma of the lung (LCNEC) is a rare disease with poor prognosis and limited treatment options. Neuroendocrine tumors frequently show overactivation mTOR pathway. Based on good activity inhibitor everolimus in different types results previous phase I trial, we evaluated efficacy safety combination carboplatin paclitaxel as upfront for patients advanced LCNEC.In this prospective, multicenter II trial chemotherapy-naive stage IV LCNEC received 5 mg daily combined...
Background For the detection of malignant mesothelioma no single biomarker with reasonable sensitivity and specificity has been described so far. Mesothelin, most prominent blood-based biomarker, is characterized by high but low sensitivity. It might be to combine biomarkers different molecular classes in order improve overall performance. The aim this study was assess performance combination mesothelin miR-103a-3p as for mesothelioma. Methods/Principal Findings Mesothelin concentration...
The use of circulating microRNAs as biomarkers has opened new opportunities for diagnosis cancer because exhibit tumor-specific expression profiles. aim this study was the identification in human plasma potential malignant mesothelioma. For discovery, TaqMan Low Density Array Human MicroRNA Cards were used to analyze 377 samples from 21 mesothelioma patients and asbestos-exposed controls. verification, individual microRNA assays quantitative real-time PCR 22 44 miR-132-3p showed different...
Ziel/Aim: Optimal duration of immune checkpoint blocker (ICB)-treatment in lung cancer has not been determined yet. One five patients treated with first-line ICB achieves durable responses for≥2 years. Treatment continuation beyond 2 years impacts on economic burden and might cause avoidable toxicities. Thus, safe discontinuation strategies represent an urgent medical need.
Lung cancer is the commonest cause of cancer-related death worldwide and poses a significant respiratory disease burden. Little known about provision lung care across Europe. The overall aim Task Force was to investigate current practice in undertook four projects: 1) narrative literature search on quality management cancer; 2) survey national local infrastructure for Europe; 3) benchmarking project (inter)national guidelines 4) feasibility study prospective data collection pan-European...
Summary Introduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined cetuximab/carboplatin/paclitaxel untreated stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Methods Patients were randomized 2:1 to arm ( N =60; 4 mg/kg, weekly; cetuximab, initial dose 400 mg/m 2 subsequent doses 250...
Chemotherapy plus immune-checkpoint inhibitor (CTx+ICI) therapy has become the preferred 1st line treatment in patients with metastatic NSCLC without oncogenic driven mutations. However, optimal subsequent 2nd is not defined and several alternatives exist. The purpose of this analysis was to evaluate efficacy docetaxel ramucirumab (D+R) initiated after failure CTx+ICI.Retrospective data were collected during routine care from German thoracic oncology centers. Only who had received at least...
The aim of this study was to analyze the frequency Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for diagnosis SCLC, response first line treatment as well prognostic impact on overall survival (OS). We analyzed a total 294 patients (m, n = 184; f, 110) with SCLC (stage IIIA, 32; IIIB, 87; IV, 175) diagnosed our institution between January 2005 December 2008. Patient's characteristics comprising age, gender, histology were included into...
Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With latency period up 50 years the incidence of MM still increasing, even in countries that banned Secondary prevention has been established provide persons at risk regular health examinations. An earlier detection with tumor markers might improve therapeutic options. Previously, we have developed new blood-based assay for protein marker calretinin. Aim this study was verification an independent...
Malignant pleural mesothelioma (MPM) is a tumour arising from cavities with poor prognosis. Multimodality treatment pemetrexed combined cisplatin shows unsatisfying response-rates of 40%. The reasons for the rather efficacy chemotherapeutic are largely unknown. However, it conceivable that DNA repair mechanisms lead to an impaired therapy response. We hypothesize major role homologous recombination (HR) genome stability and survival this tumour. Therefore, we analysed genes compiled under...
Background: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was evaluate efficacy ramucirumab plus docetaxel (R + D) as third-line treatment failure a first-line platinum-based chemotherapy second-line ICI in patients non-small-cell lung cancer (NSCLC) stage IV. Methods: Retrospective data were collected from 9...